Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | BCL6 | P41182 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11970085 | 0.87 | JAK3 (0.56) | CHEK1FLT3SYKEGFRBTK | |
| SCHEMBL4973526 | 0.81 | EGFR (0.59) | CHEK1FLT3SYKEGFRBTK | |
| SCHEMBL4975493 | 0.79 | EGFR (0.59) | CHEK1FLT3SYKEGFRBTK | |
| SCHEMBL4971601 | 0.79 | JAK3 (0.71) | CHEK1FLT3SYKEGFRBTK | |
| SCHEMBL11969795 | 0.76 | SYK (0.37) | SYKEGFRKMT2AROCK2ROCK1 | |
| SCHEMBL14029710 | 0.76 | EGFR (0.64) | CHEK1FLT3SYKEGFRBTK | |
| SCHEMBL653332 | 0.74 | SMN1; SMN2 (0.46) | SYKEGFRBTKROCK2ROCK1 | |
| SCHEMBL1115866 | 0.72 | JAK2 (0.44) | FLT3SYKBTKJAK3KMT2A | |
| SCHEMBL656737 | 0.71 | SYK (0.55) | FLT3SYKBTKJAK3KMT2A | |
| SCHEMBL14441067 | 0.71 | JAK3 (0.69) | FLT3EGFRBTKJAK3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | CHEK1 615/4885FLT3 32/4885SYK 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.